Super Religare Laboratories

Fortis Healthcare will use the entire proceeds from its 64 percent stake in Dental Corporation Holdings Ltd (DC), Australia to pare debt, says Vishal Bali, Global CEO. The company's stake in DC will be sold to Bupa for 270 million Australian dollar (around Rs 1,554.36 crore) by March 2013.

Private funding is manna; consolidation is priority: Fortis

Vishal Bali, group CEO,Fortis Healthcare explains to CNBC-TV18 that the private funding from IFC and Jacob Ballas has resulted in holding company Super Religare Laboratories turning debt-free. He added that though the company was keen on inorganic growth, the current priority is consolidation

Fortis Healthcare up 3% on equity infusion in SRL

Shares of healthcare chain Fortis Healthcare rose as much as 2.8% to intraday high of Rs 103.45 on Wednesday as its diagnositc chain subsidiary Super Religare Laboratories (SRL) has signed definitive agreements with NYLIM Jacob Ballas India Fund III LLC, Mauritius and International Finance Corporation.

Fortis diagnostic arm SRL to get Rs 370 cr PE investment

Hospital chain Fortis Healthcare on Wednesday said its diagnostic chain arm Super Religare Laboratories has signed definitive agreements with NYLIM Jacob Ballas India Fund III LLC, Mauritius and International Finance Corp for an equity infusion of Rs 370 crore.

Piramal Healthcare to be renamed Piramal Enterprises

Drugmaker Piramal Healthcare Ltd said its board has approved changing the company's name to Piramal Enterprises Ltd to appropriately reflect changes in its business profile.

Budget Reactions: Healthcare sector's got some incentives, says Religare Labs

Sanjeev K Chaudhry, CEO, Super Religare Laboratories is happy with what the Budget has delievred towards the healthcare sector.

Fortis Healthcare earmarks Rs 4bn as capex in FY12

Hospital chain Fortis Healthcare plans to spend about Rs 4 billion to raise its bed capacity by a quarter in a year, its finance chief said on Friday.

Avigo Capital to buy 9.27% in Super Religare Labs

Private equity firm Avigo Capital Partners said on Monday it has signed a share purchase agreement to buy 9.27% equity in Super Religare Laboratories Ltd (SRL) for Rs 100 crore.

Avigo Capital Partners picks up 9.27% stake in SRL

Private equity fund Avigo Capital Partners today said it has picked up a 9.27% stake in a pre-IPO placement in Super Religare Laboratories (SRL) for an aggregate amount of around Rs 100 crore.

Fortis board gives nod to buy 86% of SRL

Fortis Healthcare has announced it has received an in-principle approval from the board to acquire 86% in Super Religare Laboratories (SRL). However, there are a lot of unanswered questions reports CNBC-TV18's Nayantara Rai.

Fortis Health to sell 86% stake in Super Religare Lab

Fortis Healthcare (India) is going to sell 86% stake in Super Religare Laboratories ahead of its public issue for an undisclosed amount, reports CNBC-TV18. It touched an intraday high of Rs 164.95 and an intraday low of Rs 162.40. At 09:32 hrs the share was quoting at Rs 163, up Rs 1.25, or 0.77%.